Synovus Financial Corp bought a new stake in shares of Cambrex Co. (NYSE:CBM) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 9,782 shares of the biotechnology company’s stock, valued at approximately $540,000.
Other large investors have also made changes to their positions in the company. Creative Planning raised its stake in shares of Cambrex by 162.6% during the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 1,093 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Cambrex by 9.3% during the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 150 shares in the last quarter. Aperio Group LLC raised its stake in shares of Cambrex by 10.3% during the second quarter. Aperio Group LLC now owns 10,528 shares of the biotechnology company’s stock valued at $629,000 after acquiring an additional 986 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its stake in shares of Cambrex by 7.5% during the second quarter. Municipal Employees Retirement System of Michigan now owns 9,760 shares of the biotechnology company’s stock valued at $583,000 after acquiring an additional 680 shares in the last quarter. Finally, NGAM Advisors L.P. raised its stake in Cambrex by 2.4% in the second quarter. NGAM Advisors L.P. now owns 19,452 shares of the biotechnology company’s stock worth $1,162,000 after buying an additional 463 shares in the last quarter.
In related news, CEO Steven M. Klosk sold 4,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $54.96, for a total transaction of $219,840.00. Following the completion of the transaction, the chief executive officer now owns 87,328 shares in the company, valued at approximately $4,799,546.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.48% of the company’s stock.
Shares of Cambrex Co. (NYSE:CBM) opened at $49.65 on Friday. Cambrex Co. has a 1-year low of $42.55 and a 1-year high of $62.95. The company has a market cap of $1,630.00, a price-to-earnings ratio of 15.51, a price-to-earnings-growth ratio of 1.10 and a beta of 2.26.
Cambrex (NYSE:CBM) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.47 by $0.08. The company had revenue of $112.60 million for the quarter, compared to analyst estimates of $108.44 million. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The firm’s revenue was up 13.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.47 earnings per share. analysts predict that Cambrex Co. will post 2.97 EPS for the current fiscal year.
A number of brokerages recently commented on CBM. Craig Hallum reissued a “buy” rating and issued a $60.00 price objective (down previously from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. ValuEngine lowered shares of Cambrex from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Finally, BidaskClub lowered shares of Cambrex from a “hold” rating to a “sell” rating in a report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $62.33.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/09/synovus-financial-corp-buys-new-stake-in-cambrex-co-cbm.html.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Co. and related companies with MarketBeat.com's FREE daily email newsletter.